ZYME (Zymeworks) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZYME Zymeworks Inc ZYME
67 GF Score
Price $24.66
GF Value $25.77
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zymeworks FFO per Share?

FFO per Share only applies to REITs.

ZYME
67GF Score
Zymeworks Inc ZYME
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (ZYME) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be undervalued. The current stock price of $24.66 is trading 4.3% below its estimated GF Value™ of $25.77. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for ZYME:

  • FFO per Share:
  • GF Value™: $25.77 vs. price of $24.66 (4.3% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
67GF Score

Get the complete analysis for ZYME

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.66
Price
$25.77
GF Value